The Swiss Market Index was flat on Tuesday, closing 0.02% lower, amid renewed hopes of a resolution to the Middle East war as global heads of state and government gather at this week's UN General Assembly in the US.
Iran is willing to reopen the Strait of Hormuz within seven days if the US lifts its blockade on Iranian ports, eases its military pressure and officially expresses its desire to resolve the issue diplomatically, a senior Iranian official told Reuters.
Back home, Switzerland's current account surplus rose to 23.66 billion francs in the second quarter from the revised 16.52 billion francs in the prior three-month period, according to data from the Swiss National Bank (SNBN.SW).
On the real estate front, an analysis by UBS Group (UBSG.SW) found that Zurich faces the highest housing bubble risk globally amid rising affordability pressures. Among the 23 major cities included in the 2026 Global Real Estate Bubble Index sample, Geneva was among those in the elevated risk category.
"Over the last 20 years, Zurich has experienced the strongest increase in housing prices among the cities covered by the study, driven by low interest rates and significant supply constraints. The market remained exceptionally tight, with vacancy rates close to zero and the supply of owner-occupied homes far below historical levels. Strong competitiveness and continued demand from international talent, particularly in technology and artificial intelligence, have fueled housing demand," UBS said. "However, bubble risk remains high, with Zurich's exceptionally high and still-rising price-to-rent ratio reflecting the market's increasing dependence on low financing costs."
Speaking of UBS, the Swiss banking group agreed to pay 5 million euros as part of a settlement with the Dutch Public Prosecution Service to resolve a legacy matter tied to an investigation against Credit Suisse AG related to inaccurate tax returns filed by 12 former clients in the Netherlands. UBS noted that the deal does not constitute a recognition of criminal liability. At the end of the trading day, UBS shares shed 3.40%.
Roche (RO.SW) reported that its phase 2 study evaluating the efficacy, safety and tolerability of once-weekly enicepatide in adults with type 2 diabetes and overweight or obesity met both primary endpoints. The investigational subcutaneous injectable demonstrated a reduction in blood glucose and body weight at 48 weeks. The Swiss pharmaceutical major's stock was up 0.54% at closing.